Press releases
- Twist Bioscience Reports Fiscal Second Quarter 2024 Financial Results
- Twist Bioscience to Report Fiscal 2024 Second Quarter Financial Results on Thursday, May 2, 2024
- Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations
- Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome Sequencing
- Twist Bioscience to Present at Upcoming Investor Conferences
- Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System
- Twist Bioscience Launches cfDNA Library Preparation Kit for Liquid Biopsy Applications
- Twist Bioscience Unveils Differentiated Ultra High-Throughput Library Preparation Solution at AGBT
More ▼
Key statistics
On Friday, Twist Bioscience Corp (0ME:FRA) closed at 31.63, -17.89% below its 52-week high of 38.52, set on Feb 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 32.08 |
---|---|
High | 32.08 |
Low | 31.63 |
Bid | 37.53 |
Offer | 39.03 |
Previous close | 29.66 |
Average volume | 178.50 |
---|---|
Shares outstanding | 57.82m |
Free float | 56.38m |
P/E (TTM) | -- |
Market cap | 2.38bn USD |
EPS (TTM) | -3.35 USD |
Data delayed at least 15 minutes, as of May 03 2024 14:29 BST.
More ▼